Selective endothelin receptor blockade in resistant hypertension: Results of the DORADO trial

Research output: Contribution to journalArticlepeer-review

Abstract

Effective treatment of resistant hypertension still remains an unmet goal of antihypertensive drug treatment. The DORADO trial recently evaluated the efficacy and safety profile of the selective endothelin receptor blocker darusentan in almost 400 hypertensive patients treated with more than four antihypertensive drugs (including a diuretic) but without effective blood pressure control. The trial results show that > 50% of patients treated with the drug exhibit clinical blood pressure <140/90 mmHg and well-controlled ambulatory blood pressure values. Darusentan, however, was associated with a high incidence of peripheral edema and fluid retention, a side effect that may reduce the safety profile of the drug and its tolerability. Although these data are promising, the drug requires further evaluation, with particularly regard to the long term.

Original languageEnglish
Pages (from-to)153-155
Number of pages3
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 2011

Keywords

  • Blood pressure control
  • Darusentan
  • Endothelin receptor blocker
  • Resistant hypertension

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'Selective endothelin receptor blockade in resistant hypertension: Results of the DORADO trial'. Together they form a unique fingerprint.

Cite this